FDA Removes Black Box Warning Labels from Hormone Replacement Therapy for Menopause

The Food and Drug Administration announced Monday it will remove broad “black box” warning labels from hormone replacement therapy (HRT) for menopause, a significant policy reversal that could affect millions of American women.

The decision follows a comprehensive review of scientific literature by an FDA expert panel in July and a subsequent public comment period. Manufacturers are now expected to update their product labeling to remove references to risks of cardiovascular disease, breast cancer, and probable dementia that have been prominently featured for over two decades.

“The label was designed to frighten women and to silence doctors,” Department of Health and Human Services Secretary Robert F. Kennedy Jr. said during Monday’s announcement. “The consequences have been devastating.”

The agency will, however, maintain the boxed warning for endometrial cancer on systemic estrogen-only products. The updated recommendations will advise women to start HRT within 10 years of menopause onset or before age 60 for systemic treatment.

This policy shift represents a dramatic reversal from the aftermath of a 2002 study that led to a collapse in HRT prescriptions. That research, now widely criticized as flawed, found a small increased risk of breast cancer—less than a tenth of 1% per year for an individual woman—but its results were broadly misinterpreted, leading to what some medical experts call unwarranted fear. A recent 2024 study revealed that only 5% of American women currently use HRT for menopause symptoms.

The implications are substantial, as approximately 80% of women experience menopause symptoms that can persist for years. Research indicates women who begin HRT before age 60 experience a reduction in all-cause mortality. According to data cited by HHS, hormone therapy may reduce cardiovascular disease risk by up to 50%, Alzheimer’s disease by 35%, and bone fractures by up to 60%.

FDA Commissioner Marty Makary, M.D., a former surgical oncologist at Johns Hopkins, criticized what he termed “medical group-think” for perpetuating fear around HRT. “No clinical trial has ever shown that HRT increases the risk of breast cancer mortality,” Makary emphasized. “How could the medical establishment get it so wrong for so long? Women deserve the same rigorous science as do men.”

The FDA simultaneously announced the approval of two new treatment options for menopausal symptoms. The first is a generic version of Premarin, a commonly prescribed HRT product, which is expected to improve affordability and access. The second approval is for a non-hormonal treatment targeting moderate to severe vasomotor symptoms, like hot flashes, designed for women unable to use hormone therapy.

During the announcement, Advanced Research Projects Agency for Health Director Alicia Jackson, Ph.D., underscored the scientific consensus: “The science is clear… estrogen is one of the most effective longevity interventions for women. It is time for American healthcare to catch up to American science.”

When questioned about the FDA’s methodology, Makary explained the agency opted for an expert panel rather than a traditional advisory committee to encourage more spontaneous and unencumbered debate among medical experts. He described advisory committees as “bureaucratic, long, often conflicted and very expensive,” noting this approach reflects a broader shift at the FDA. The agency’s comprehensive review of HRT is expected to be published in the Journal of the American Medical Association.

Kennedy concluded the announcement with a political flourish: “For the first time in a generation, the FDA is standing with science, and standing with women. That’s what it means to Make America Healthy Again.”

The policy change could potentially transform treatment approaches for millions of women experiencing menopause, reshaping both medical practice and public perceptions about hormone therapy after decades of controversy.